相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and l-DOPA-Induced Dyskinesia
Nilson Carlos Ferreira Junior et al.
NEUROTOXICITY RESEARCH (2020)
Endocannabinoid system and adult neurogenesis: a focused review
Sergio Oddi et al.
CURRENT OPINION IN PHARMACOLOGY (2020)
Perspectives on Cannabis-Based Therapy of Multiple Sclerosis: A Mini-Review
Miriam Mecha et al.
FRONTIERS IN CELLULAR NEUROSCIENCE (2020)
The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomes
Javier Fernandez-Ruiz
BRITISH JOURNAL OF PHARMACOLOGY (2019)
7,8,4′-Trihydroxyisoflavone, a Metabolized Product of Daidzein, Attenuates 6-Hydroxydopamine-Induced Neurotoxicity in SH-SY5Y Cells
Yong-Hyun Ko et al.
BIOMOLECULES & THERAPEUTICS (2019)
Cannabinoid receptor as a potential therapeutic target for Parkinson's Disease
Himadri Shekhaar Baul et al.
BRAIN RESEARCH BULLETIN (2019)
Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration
Jose Aguareles et al.
TRANSLATIONAL NEURODEGENERATION (2019)
Endocannabinoid System in Spinocerebellar Ataxia Type-3 and Other Autosomal-Dominant Cerebellar Ataxias: Potential Role in Pathogenesis and Expected Relevance as Neuroprotective Targets
Maria Gomez-Ruiz et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2019)
Development of An Oral Treatment with the PPAR-γ-Acting Cannabinoid VCE-003.2 Against the Inflammation-Driven Neuronal Deterioration in Experimental Parkinson's Disease
Sonia Burgaz et al.
MOLECULES (2019)
The endocannabinoid system and stroke: A focused review
Bradley Kolb et al.
BRAIN CIRCULATION (2019)
Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation
Janos Paloczi et al.
ANTIOXIDANTS & REDOX SIGNALING (2018)
β-Caryophyllene (BCP) ameliorates MPP plus induced cytotoxicity
Guifang Wang et al.
BIOMEDICINE & PHARMACOTHERAPY (2018)
In Vitro Model of Neuroinflammation: Efficacy of Cannabigerol, a Non-Psychoactive Cannabinoid
Agnese Gugliandolo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson's disease: possible involvement of different binding sites at the PPARγ receptor
Concepcion Garcia et al.
JOURNAL OF NEUROINFLAMMATION (2018)
Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system
Maria S. Aymerich et al.
BIOCHEMICAL PHARMACOLOGY (2018)
GPR55: A therapeutic target for Parkinson's disease?
Marta Celorrio et al.
NEUROPHARMACOLOGY (2017)
Neuroprotective Effect of JZL184 in MPP+-Treated SH-SY5Y Cells Through CB2 Receptors
Maria S. Aymerich et al.
MOLECULAR NEUROBIOLOGY (2016)
Can cannabinoids be a potential therapeutic tool in amyotrophic lateral sclerosis?
Sabrina Giacoppo et al.
NEURAL REGENERATION RESEARCH (2016)
THC (Δ9-Tetrahydrocannabinol) Exerts Neuroprotective Effect in Glutamate-affected Murine Primary Mesencephalic Cultures Through Restoring Mitochondrial Membrane Potential and Anti-apoptosis Involving CB1 Receptor-dependent Mechanism
Chi Huu Nguyen et al.
PHYTOTHERAPY RESEARCH (2016)
Cannabinoids to treat spinal cord injury
Angel Arevalo-Martin et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2016)
Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson's disease
Yolanda Gomez-Galvez et al.
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY (2016)
Cannabinoid-induced autophagy: Protective or death role?
Lia Costa et al.
PROSTAGLANDINS & OTHER LIPID MEDIATORS (2016)
VCE-003.2, a novel cannabigerol derivative, enhances neuronal progenitor cell survival and alleviates symptomatology in murine models of Huntington's disease
Javier Diaz-Alonso et al.
SCIENTIFIC REPORTS (2016)
Cannabinoid Type 2 (CB2) Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson's Disease
Hayate Javed et al.
FRONTIERS IN NEUROSCIENCE (2016)
CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson's disease
Young C. Chung et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2016)
Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications
Javier Fernandez-Ruiz et al.
NEUROTHERAPEUTICS (2015)
A Cannabigerol Derivative Suppresses Immune Responses and Protects Mice from Experimental Autoimmune Encephalomyelitis
Francisco J. Carrillo-Salinas et al.
PLOS ONE (2014)
An alternate binding site for PPARγ ligands
Travis S. Hughes et al.
NATURE COMMUNICATIONS (2014)
Endocannabinoid signalling in Alzheimer's disease
Nazia Maroof et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2013)
A Cannabigerol Quinone Alleviates Neuroinflammation in a Chronic Model of Multiple Sclerosis
Aitor G. Granja et al.
JOURNAL OF NEUROIMMUNE PHARMACOLOGY (2012)
?9-tetrahydrocannabinol (?9-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease
C. B. Carroll et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2012)
Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ9-THCV in animal models of Parkinson's disease
C. Garcia et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Endocannabinoids and traumatic brain injury
Esther Shohami et al.
BRITISH JOURNAL OF PHARMACOLOGY (2011)
Cannabinoid Receptor Type 1 Protects Nigrostriatal Dopaminergic Neurons against MPTP Neurotoxicity by Inhibiting Microglial Activation
Young C. Chung et al.
JOURNAL OF IMMUNOLOGY (2011)
Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors
Sandra Perez-Rial et al.
NEUROBIOLOGY OF AGING (2011)
The CB1 antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease
J. E. Kelsey et al.
BEHAVIOURAL BRAIN RESEARCH (2009)
Cannabidiol: A Promising Drug for Neurodegenerative Disorders ?
Teresa Iuvone et al.
CNS NEUROSCIENCE & THERAPEUTICS (2009)
WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease
David A. Price et al.
EUROPEAN JOURNAL OF NEUROSCIENCE (2009)
Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and α-synuclein-deleted mice
Daniel Alvarez-Fischer et al.
EXPERIMENTAL NEUROLOGY (2008)
The cannabinoid CP55,940 prolongs survival and improves locomotor activity in Drosophila melanogaster against paraquat:: Implications in Parkinson's disease
M. Jimenez-Del-Rio et al.
NEUROSCIENCE RESEARCH (2008)
Cannabinoid CB1 receptor stimulation affords neuroprotection in MPTP-induced neurotoxicity by attenuating S100B up-regulation in vitro
Teresa Iuvone et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2007)
Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease
S González et al.
BRAIN RESEARCH (2006)
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro:: Relevance to Parkinson's disease
I Lastres-Becker et al.
NEUROBIOLOGY OF DISEASE (2005)
Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism
E Fernandez-Espejo et al.
NEUROBIOLOGY OF DISEASE (2005)
分享论文
